Work

Supplementary Tables 1 - 2 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 73KB, Suppl Table 1. Multiple Dose Pharmacokinetic Parameters for MMAE Suppl Table 2. Best Clinical Response Rate by Diagnosisa (efficacy evaluable population).

DOI: 10.1158/1078-0432.22447598

Authors: Michelle A. Fanale, Andres Forero-Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, Nancy L. Bartlett

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362395087

Cites:

Cited by:

Related to: 10